

Transcriptomic analysis of asymptomatic and symptomatic severe Turkish patients in SARS-CoV-2 infection

Sadrettin Pence,¹ Burcu Caykara,¹ Halime Hanim Pence,² Saban Tekin,^{3,4} Birsen Cevher Keskin,⁴ Ali Tevfik Uncu,⁵ Ayse Ozgur Uncu,⁶ Erman Ozturk⁷

¹Department of Physiology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey ²Department of Biochemistry, Health Sciences University Faculty of Medicine, Istanbul, Turkey ³Department of Medical Biology, Health Sciences University, Faculty of Medicine, Istanbul, Turkey ⁴TUBITAK, Marmara Research Center, Gene Engineering and Biotechnology Institute, Kocaeli, Turkey ⁵Department of Molecular Biology and Genetics, Necmettin Erbakan University Faculty of Science, Konya, Turkey ⁶Department of Biotechnology, Necmettin Erbakan University Faculty of Science, Konya, Turkey ⁷Division of Hematology, Department of Internal Diseases, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey

ABSTRACT

OBJECTIVE: Coronavirus disease 2019 (COVID-19), leading to mild infection (MI), acute respiratory distress syndrome or death in different persons. Although the basis of these variabilities has not been fully elucidated, some possible findings have been encountered. In the present study, we aimed to reveal genes with different expression profiles by next-generation sequencing of RNA isolated from blood taken from infected patients to reveal molecular causes of different response.

METHODS: Two healthy, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative control individuals (NCI), two SARS-CoV-2-positive patients who have MI, and two patients who have critical infection (CI) were included in the study. Total RNA was extracted from blood samples and sequenced. Raw RNA-Seq data were analyzed on Galaxy platform for the identification of differentially expressed genes and their pathway involvements.

RESULTS: We found that 199 and 521 genes were downregulated in whole blood of COVID-19-positive CI patients compared to NCI and MI patients, respectively. We identified 21 gene ontology pathways commonly downregulated in CI patients compared to both NCI and MI, mostly associated with innate and adaptive immune responses. Three hundred and fifty-four and 600 genes were found to be upregulated compared to NCI and MI, respectively. Upregulated six pathways included genes that function in inflammatory response and inflammatory cytokine release.

CONCLUSION: The transcriptional profile of CI patients deviates more significantly from that of MI in terms of the number of differentially expressed genes, implying that genotypic differences may account for the severity of SARS-CoV-2 infection and inflammatory responses through differential regulation of gene expression. Therefore, further studies that involve whole genome analysis coupled with differential expression analysis are required in order to determine the dynamics of genotype – gene expression profile associations.

Keywords: COVID-19; gene ontology; immunity; innate; platelet activation; RNA-Seq.

Cite this article as: Pence S, Caykara B, Pence HH, Tekin S, Keskin BC, Uncu AT, et al. Transcriptomic analysis of asymptomatic and symptomatic severe Turkish patients in SARS-CoV-2 infection. North Clin Istanb 2022;9(2):122–130.



Received: December 15, 2021 Accepted: Febriary 22, 2022 Online: April 13, 2022

Correspondence: Erman OZTURK, MD. Medeniyet Universitesi Tip Fakultesi, Ic Hastaliklari Anabilim Dali, Hematoloji Bilim Dali, Istanbul, Turkey.

Tel: +90 216 606 52 00 e-mail: erman.ozturk@medeniyet.edu.tr

© Copyright 2022 by Istanbul Provincial Directorate of Health - Available online at www.northclinist.com

ne of the main agents of the seasonal cold, human coronaviruses, is known to cause pneumonia. In 2019, a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease 2019 (COVID-19) emerged, leading to acute respiratory distress syndrome, death, or asymptomatic infection in different persons [1]. SARS-CoV-2 infection is thought to be asymptomatic in at least onethird of the incidences. Approximately 40% of infected individuals remain asymptomatic [2]. In symptomatic cases, about 81% of infected humans have a mild flu-like illness, while severe or critical disease effects are seen about in 14% and 5% of infected humans, respectively. The overall case-fatality rate is estimated to be 2.3% [3]. Advanced age and the comorbidities with obesity, hypertension, or diabetes mellitus may predispose patients to an increased risk of severe disease and death [4, 5].

Although the cause of the differential response to SARS-CoV-2 infection in different patients has not been fully elucidated, some possible findings have been encountered. For instance, a study showed that patients with severe SARS-CoV-2 infection exhibit a higher antibody response to spike and nucleocapsid proteins of SARS-CoV-2, and a higher memory B-cell response to spike protein [6]. In a recent trial, platelet gene expression was differed between control and the critical ill COVID-19 patients which P-selectin expression had increased [7]. Furthermore, upper airway gene expression reveals suppression of innate immune response [8]. The entry of SARS-CoV-2 into the host cell takes place through angiotensin-converting enzyme 2 (ACE2). Variants in certain regions of the ACE2 gene may affect conformational changes and interaction in spike protein binding, protein stability, while some other variants may cause an increase in ligand-receptor affinity. In particular, variations in regulatory and non-coding genomic regions such as the ACE2 promoter may affect ACE2 expression levels, putatively leading to differential response to SARS-CoV-2 in different individuals [9].

In the present work, we aimed to reveal differentially expressed genes in blood from SARS-CoV-2-infected individuals to identify the molecular causes underlying the variation in response to SARS-CoV-2 infection in different individuals.

MATERIALS AND METHODS

Patients and Sample Collection

Ethical approval for the study was obtained from Istanbul Medeniyet University, Goztepe Training and

Highlight key points

- COVID-19 infection disease is heterogeneous and not predictable.
- Innate and adaptive immunity were downregulated in CI.
- Platelet activation and platelet degranulation pathways were exclusively upregulated in CI.
- These factors may be the cause of immunothrombosis.

Research Hospital Ethics Committee for Clinical Research (no: 2020/183, 23.03.2020). Two healthy non-infected control individuals (NCI), two SARS-CoV-2-positive patients who have mild infection (MI), and two SARS-CoV-2-positive patients who have critical infection (CI), as described before [10], were included in the study. Patients were treated as recommended by the TC Ministry of Health. Favipravir was administered to both groups, but patients treated in intensive care unit received steroids. Blood samples were collected from patients in DNA/RNA shield tubes through an indwelling intravenous catheter. Samples were transferred to TUBITAK, Marmara Research Center, Gene Engineering and Biotechnology Institute and RNA isolation process was completed within 24 h in biosafety level 3 laboratory.

RNA Isolation and Quality Assessment

Total RNA was extracted from blood samples using Zymo Quick-RNA[™] Whole Blood (Zymo Research Corp, Irvine, U.S.A Catalog No. R1201), according to the manufacturer's instructions with some modifications. For all three patient groups, 300 µl whole blood was used. After the DNase I treatment in column, RNA was eluted from the column with 15 μ l RNase-free water. The quality and quantity of resulting total RNA samples were controlled by Nanodrop spectrophotometer (Thermo Scientific[™] NanoDrop) and Qubit (Thermo Fischer Qubit[™] 4 Fluorometer). The A260/A280 ratio of purified RNAs was between 1.8 and 2.0, and A260/A230 ratio ranged between 1.8 and 2.1. The RNA integrity number (RIN) was assessed using the Bioanalyzer (Agilent Technologies 2100 Bioanalyzer) for all RNA samples. RNA samples with a RIN number >7 were subjected to cDNA library preparation protocol. The concentration of RNA was measured using the RNA-BR protocol of the Qubit 2.0 Fluorometer (Thermo Fischer Life Technologies).

Transcriptome Sequencing

For the removal of mitochondrial and cytoplasmic rRNA from total RNA samples, Ribo-Zero Gold rRNA depletion protocol (Illumina TruSeq Stranded Total RNA Library Prep Gold kit, Cat No: 20020599) was used. Depleted and purified samples (200 ng RNA) underwent enzymatic fragmentation. After the first and second strand cDNA synthesis, adenylation, adapter ligation, and amplification procedures were performed with some modifications in the TruSeq Stranded Total RNA protocol (TruSeq Stranded Total RNA Library Prep Gold kit Illumina, Cat no. 20020599). For the adapter ligation step, IDT for Illumina TruSeq RNA unique dual indexes (UDIs) was used (Illumina, Cat no. 20022371). Enrichment of the DNA fragments that have adapter sequences on both ends was carried out by 15 cycles of PCR. After the clean-up procedure of the amplified DNA with AM-Pure XP beads, the size and purity of the libraries were assessed with Bioanalyzer using the HS DNA Kit (Agilent Technologies 2100 Bioanalyzer). To obtain optimum cluster densities and high-quality data, library quantification was performed by qPCR (KAPA Library Quantification Kits KK4601). The quantity of the libraries was controlled using three replications and two dilutions for each sample for accurate quantification. After the calculation, master pool was loaded onto the NovaSeq 6000 platform, using 150 bp paired ends sequencing and S1 flow cell. The quality score of the run (QC30) was 80.

RNA-Seq Data Analysis

Raw RNA-Seq data were analyzed using Galaxy platform [11]. Trimmomatic tool was used to eliminate short reads and sequencing adapters (Galaxy Version 0.38.0) [12]. Remaining reads were aligned to human reference genome hg38 using STAR (Version 2.7.5b) to map the reads in their locations in the reference genome [13]. Gene model for hg38 was chosen as ensGene and retrieved from UCSC Genome Browser (https:// genome.ucsc.edu/cgi-bin/hgGateway). Quantification of mapped transcripts was done by feature counts tool [14]. This step can simply be summarized as the determination of the number of RNA-Seq reads obtained from each gene/mapped genomic location. Following the quantification process, Deseq2 [15] was used for the identification of differentially expressed genes. Functional analysis of DEGs was conducted through David (v6.8) [16]. The threshold for statistical significance was chosen as 0.05 after multiple testing correction.

Table 1.	Demographic and clinical characteristics of the
patients	

Patients	Age	Sex	Groups
ES	25	F	NCI
OE	27	F	NCI
IB	37	F	MI
ST	35	М	MI
AC	76	М	CI
ZY	78	F	CI

F: Female; M: Male; NCI: SARS-CoV-2-negative control individuals; MI: Mild infection; CI: Critical infection.




FIGURE 1. Venn diagrams of differentially expressed gene sets in CI patients. (A) Numbers of downregulated genes in CI patients versus NCI and CI versus MI are displayed. (B) Numbers of upregulated genes in CI patients versus NCI and CI versus MI are displayed.

 $\ensuremath{\mathsf{NCI}}$ SARS-CoV-2-negative control individuals; MI: Mild infection; CI: Critical infection.

Differential gene expression patterns of SARS-CoV-2 were obtained by RNA-Seq transcriptome sequencing performed on whole-blood RNA samples of each group. Differentially expressed genes in CI patients with respect to NCI and MI were determined based on a cutoff log2-fold change value of 2. Gene ontology (GO) terms were assigned to the differentially expressed genes and GO enrichment analysis was performed to determine the up- and down-regulated pathways with putative relations to SARS-CoV-2 infection response in CI patients.




FIGURE 2. Heat map of differential gene expression among CI, MI, and NCI whole-blood samples. The graphical display is based on a cutoff log2-fold change value of 2.

RESULTS

Six samples were evaluated in three groups abbreviated as CI, MI, and NCI (Table 1). Patients who have CI died at the intensive care unit. According to the results of the differential expression analysis, 199 and 521 genes were found to be downregulated in whole blood of CI patients compared to NCI and MI, respectively (Table 1), with 148 genes found to be commonly downregulated in both comparisons (Fig. 1a). GO enrichment analysis identified 21 GO pathways commonly downregulated in CI patients with respect to both NCI and MI (Table 2). Majority of these common downregulated GO pathways (17 pathways) were directly associated with innate and adaptive immune responses. Remaining downregulated GO pathways that were not common between the two comparisons (CI vs. NCI and CI vs. MI) were also associated with the immune system responses, including pathways such as innate immune response (GO:0045087), inflammatory response (GO:0006954), B-cell activation (GO:0042113), B-cell receptor signaling (GO:0050853), T-cell differentiation (GO:0030217), and chemokine-mediated signaling (GO:0070098) (Table 2).

When genes differentially upregulated in whole blood of CI patients were examined, 354 and 600 genes were found to be upregulated compared to NCI and MI, respectively (Table 2), with 273 upregulated genes common in both comparisons (Fig. 1b). The results of the GO enrichment analysis displayed six pathways commonly upregulated in both comparative conditions (Table 3). These pathways included genes that function in inflammatory response and inflammatory cytokine release (Table 3). Strikingly, platelet activation (GO:0030168) and platelet degranulation (GO:0002576) pathways were exclusively upregulated in CI patients compared to MI but not to NCI. Heat map of differential expression observed among CI, NCI and MI blood samples is provided as Figure 2.

DISCUSSION

Differentially expressed genes in CI patients compared to NCI and MI were identified as a result of the study. A log2-fold change value of 2 was used as a cutoff to accept genes as differentially expressed. It is feasible to adjust lower cutoff values, which would result in the identification of a higher number of genes as differentially expressed. However, it is useful to set high stringency statistical analysis conditions to compensate for the relatively narrow sample size in cases where sampling from a high number of individuals is not feasible. Nevertheless, a significantly high number of genes were found to be differentially expressed in CI patients compared to both NCI and MI individuals when differentially expressed genes were determined based on a statistically safe cutoff threshold. GO enrichment analysis determined the up- and down-regulated pathways. We identified 21 GO pathways commonly downregulated in CI patients compared to both NCI and MI. Downregulated 17 GO pathways were directly associated with innate and adaptive immune responses. Three hundred and fifty four and 600 genes

GO pathways downregulated in CI patients					
CI versus NCI*	CI versus MI*				
GO:0006955: Immune response	GO:0050776: Regulation of immune response				
GO:0007166: Cell surface receptor signaling pathway	GO:0002250: Adaptive immune response				
GO:0006968: Cellular defense response	GO:0006955: Immune response				
GO:0050776: Regulation of immune response	GO:0006968: Cellular defense response				
GO:0031295: T-cell costimulation	GO:0007166: Cell surface receptor signaling pathway				
GO:0046641: Positive regulation of alpha-beta-T-cell proliferation	hsa04640: Hematopoietic cell lineage				
hsa05340: Primary immunodeficiency	hsa05340: Primary immunodeficiency				
hsa04660: T-cell receptor signaling pathway	GO:0042110: T-cell activation				
GO:0050852: T-cell receptor signaling pathway	GO:0031295: T-cell costimulation				
GO:0007169: Transmembrane receptor protein tyrosine kinase signaling pathway	<i>GO:0007169: Transmembrane receptor protein tyrosine kinase signaling pathway</i>				
GO:0042110: T-cell activation	GO:0050852: T-cell receptor signaling pathway				
hsa04650: Natural killer cell-mediated cytotoxicity	GO:0042113: B-cell activation				
GO:0002250: Adaptive immune response	GO:0050853: B-cell receptor signaling pathway				
GO:0042102: Positive regulation of T-cell proliferation	hsa04660: T-cell receptor signaling pathway				
hsa04640: Hematopoietic cell lineage	GO:0045060: Negative thymic T-cell selection				
GO:0050850: Positive regulation of calcium-mediated signaling	GO:0045086: Positive regulation of interleukin-2 biosynthetic				
hsa04514: CAMs	process				
GO:0045060: Negative thymic T-cell selection	GO:0070098: Chemokine-mediated signaling pathway				
GO:0045086: Positive regulation of interleukin-2 biosynthetic	GO:0045087: Innate immune response				
process	hsa04612: Antigen processing and presentation				
, GO:0030217: T-cell differentiation	GO:0046641: Positive regulation of alpha-beta-T-cell proliferation				
hsa05332: Graft-versus-host disease	hsa04662: B-cell receptor signaling pathway				
hsa05330: Allograft rejection	GO:0006954: Inflammatory response				
hsa04940: Type I diabetes mellitus	hsa04650: Natural killer cell-mediated cytotoxicity				
hsa04612: Antigen processing and presentation	hsa04514: CAMs				
hsa04060: Cytokine-cytokine receptor interaction	hsa04060: Cytokine-cytokine receptor interaction				
	GO:0006959: Humoral immune response				
	GO:0050850: Positive regulation of calcium-mediated signaling				
	GO:0042102: Positive regulation of T-cell proliferation				
	GO:0071345: Cellular response to cytokine stimulus				
	GO:0031529: Ruffle organization				
	GO:0006935: Chemotaxis				

*: Pathways commonly downregulated in both comparisons are given in italics; GO: Gene ontology; MI: Mild infection; CI: Critical infection; NCI: SARS-CoV-2-negative control individuals; CAMs: Cell adhesion molecules.

were found to be upregulated compared to NCI and MI, respectively. Upregulated six pathways included genes that function in inflammatory response and inflammatory cytokine release.

Immune responses to SARS-CoV-2 infection include tissue barriers, innate and adaptive cells, and mediators. Once the virus infects respiratory epithelial cells, viral peptides are presented through Class I major histocompatibility complex (MHC) proteins to CD8+ cytotoxic T cells, leading to the activation and development of virus-specific effector and memory T cells. In short time, virus is recognized by antigen-presenting cells which present viral peptides to CD4+ T cells through MHC-Class-II molecules, while B cells can directly rec-

CI versus NCI* GO:0045087: Innate immune response GO:0006954: Inflammatory response GO:0006915: Apoptotic process GO:0071222: Cellular response to lipopolysaccharide GO:0061621: Canonical glycolysis GO:0006953: Acute-phase response GO:0050832: Defense response to fungus GO:0042742: Defense response to bacterium GO:0006096: Glycolytic process GO:0051092: Positive regulation of NF-kappa B transcription fac-	CI versus MI* GO:0006953: Acute-phase response GO:0071222: Cellular response to lipopolysaccharide GO:0002576: Platelet degranulation GO:0006954: Inflammatory response GO:0045087: Innate immune response GO:0032720: Negative regulation of tumor necrosis factor pro duction GO:0032715: Negative regulation of interleukin-6 production GO:0030168: Platelet activation
GO:0006954: Inflammatory response GO:0006915: Apoptotic process GO:0071222: Cellular response to lipopolysaccharide GO:0061621: Canonical glycolysis GO:0006953: Acute-phase response GO:0050832: Defense response to fungus GO:0042742: Defense response to bacterium GO:0006096: Glycolytic process	 GO:0071222: Cellular response to lipopolysaccharide GO:0002576: Platelet degranulation GO:0006954: Inflammatory response GO:0045087: Innate immune response GO:0032720: Negative regulation of tumor necrosis factor pro duction GO:0032715: Negative regulation of interleukin-6 production
GO:0006915: Apoptotic process GO:0071222: Cellular response to lipopolysaccharide GO:0061621: Canonical glycolysis GO:0006953: Acute-phase response GO:0050832: Defense response to fungus GO:0042742: Defense response to bacterium GO:0006096: Glycolytic process	 GO:0002576: Platelet degranulation GO:0006954: Inflammatory response GO:0045087: Innate immune response GO:0032720: Negative regulation of tumor necrosis factor production GO:0032715: Negative regulation of interleukin-6 production
GO:0071222: Cellular response to lipopolysaccharide GO:0061621: Canonical glycolysis GO:0006953: Acute-phase response GO:0050832: Defense response to fungus GO:0042742: Defense response to bacterium GO:0006096: Glycolytic process	GO:0006954: Inflammatory response GO:0045087: Innate immune response GO:0032720: Negative regulation of tumor necrosis factor pro duction GO:0032715: Negative regulation of interleukin-6 production
50:0061621: Canonical glycolysis 50:0006953: Acute-phase response 50:0050832: Defense response to fungus 50:0042742: Defense response to bacterium 50:0006096: Glycolytic process	GO:0045087: Innate immune response GO:0032720: Negative regulation of tumor necrosis factor pro duction GO:0032715: Negative regulation of interleukin-6 production
GO:0006953: Acute-phase response GO:0050832: Defense response to fungus GO:0042742: Defense response to bacterium GO:0006096: Glycolytic process	GO:0032720: Negative regulation of tumor necrosis factor pro duction GO:0032715: Negative regulation of interleukin-6 production
GO:0050832: Defense response to fungus GO:0042742: Defense response to bacterium GO:0006096: Glycolytic process	duction GO:0032715: Negative regulation of interleukin-6 production
GO:0042742: Defense response to bacterium GO:0006096: Glycolytic process	GO:0032715: Negative regulation of interleukin-6 production
GO:0006096: Glycolytic process	
	GO:0030168: Platelet activation
O:0051092: Positive regulation of NF-kappa B transcription fac-	
or activity	
nsa04066: HIF-1 signaling pathway	
sa05132: Salmonella infection	
nsa04668: TNF signaling pathway	
nsa05140: Leishmaniasis	
nsa05134: Legionellosis	
GO:0032496: Response to lipopolysaccharide	
GO:0032720: Negative regulation of tumor necrosis factor pro-	
luction	
GO:0050900: Leukocyte migration	
GO:0032715: Negative regulation of interleukin-6 production	
GO:0050830: Defense response to Gram-positive bacterium	
sa04620: Toll-like receptor signaling pathway	
nsa00010: Glycolysis/gluconeogenesis	
60:0031663: Lipopolysaccharide-mediated signaling pathway	

*: Pathways commonly upregulated comparisons are given in italics; GO: Gene ontology; MI: Mild infection; CI: Critical infection; NCI: SARS-CoV-2-negative control individuals.

ognize the virus and interact with CD4+ T cells. Immunoglobulin (Ig) M virus-specific antibody response is observed within the 1st week following symptoms and IgG antibodies follow that, mostly retaining a lifelong immunity [17].

A wide variety of mild, moderate, severe, and rapidly progressive clinical findings are observed in patients with SARS-CoV-2 [18]. SARS-CoV-2 infection is not simply common cold and majority of SARS-CoV-2-infected individuals might have no or mild symptoms. The mortality rate of SARS-CoV-2 is estimated as 3–4%, which is higher than mortality rate (<0.1%) of influenza infection [19]. High prevalence of SARS-CoV-2 plasma viral load was found related to increased respiratory disease severity, low lymphocyte counts, and increased inflammation markers such as C-reactive protein and interleukin (IL)-6 [20]. The cytokine storm in severe COVID-19 is characterized by Pedersen et al. [19] and decreased interferon (IFN)-γ expression in CD4+ T cells, lymphopenia (in CD4+ and CD8+ T cells), and increased cytokine levels (IL-6, IL-10, and TNF- α) were found to be associated with severe COVID-19, likely through increased pulmonary pathology, T-cell depletion, and CD4+ T cell dysfunction. Another study showed that the NODlike receptor family, pyrin domain-containing 3 inflammasome in peripheral blood mononuclear cells and tissues of postmortem patients is activated in response to SARS-CoV-2 infection. Higher levels of Casp1p20 and IL-18 which are inflammasome-derived products in the sera were found associated with COVID-19 severity and poor clinical outcome, including IL-6 and lactate dehydrogenase [21]. Furthermore, viral RNA is sensed by toll-like receptor TLR3, TLR7, TLR8, and TLR9, activating the NF-κB pathway and pro-inflammatory cytokines, initiating virus-induced inflammation. Host immune signaling proteins are targeted by SARS-CoV-2 viral proteins. For instance, IFN pathway is targeted by Nsp13, Nsp15, and open reading frame ORF9b [17]. SARS-CoV infection was indicated a depressed innate immune response. with decreased expression of genes related to toll-like receptor and IL signaling [22-24]. As shown in Table 2, gene expression of innate and adaptive immune response is downregulated in critical ill patients. Furthermore, Mick et al. [8] were represented gene expression in the upper airway tissue and showed that gene expression of innate immune response diminished compared to other virus infections. According to our results, majority of downregulated GO pathways in CI (17 pathways) were directly associated with innate and adaptive immune responses, a result that is attributed to the corticosteroid treatment-associated downregulation of systemic and pulmonary inflammation. For instance, CD4, CD6, CD3g, TLR7, and IL32 were common genes downregulated in CI versus NCI or MI patients. Remaining downregulated GO pathways in CI versus NCI and CI versus MI were also associated with the immune system responses, including pathways such as innate immune response (GO:0045087), inflammatory response (GO:0006954), B-cell activation (GO:0042113), B-cell receptor signaling (GO:0050853), T-cell differentiation (GO:0030217), and chemokine-mediated signaling (GO:0070098). Some of the associated genes were TLR7, IL-27 receptor subunit alpha, IL-5 receptor subunit alpha, NLR family CARD domain-containing protein 3, IL-32, T-cell receptor gamma variable 2, CD molecules (CD2, CD4, CD6, CD7, CD22, CD74, etc.), Ig superfamily member 8, and B and T lymphocyte associated which are given in Table 2. Our results show that the expression of immune elements that should be activated by SARS-CoV-2 infection is suppressed in severe patients. On the other hand, when we examine genes that are upregulated, 354 and 600 genes were found to be upregulated compared to NCI and MI, respectively. The results of the GO enrichment analysis displayed six pathways including genes that function in inflammato-

ry response and inflammatory cytokine release. TLR4, TLR8, IL4 receptor, IL-1 receptor-like 1, lactate dehydrogenase A, NLR family CARD domain-containing 4, CD24, CD63, and CD177 were upregulated in CI versus NCI and/or MI (Table 3). The fact that some immune elements are upregulated, and some are downregulated may indicate an impaired immune response in severe patients. Interestingly, it was observed that some members of the matrix metalloproteinase (MMP) family (MMP-8-9 and 25) had upregulated expression levels in CI patients which may indicate the breakdown of extracellular matrix in intensive care patients. In addition, human phenotype ontology analysis of the entire set of upregulated genes in CI patients versus MI displayed "abnormal thrombosis" as the top human phenotype (HP: 0001977) associated with the gene set. The contemporary activation of immune, inflammatory, and coagulation pathways is consistent with the concept of immunothrombosis [2]. These two processes are initially triggered by a diffuse endothelial dysfunction induced by SARS-CoV-2 through ACE-2 receptors and the transmembrane protease serine 2 that are currently recognized as specific sites by which the virus enters into the vascular system. One of the worst features of COVID-19 is a severe coagulopathy with an increased risk of thromboembolic complications and an incidence of venous thromboembolism (VTE) of about 25%. In critically ill patients, VTE incidence was 25% and higher than the non-COVID patients [25]. Furthermore, arterial thrombosis is not rare (3.7%) [26]. As shown in Table 3 genes that function in inflammatory response, inflammatory cytokine release, platelet activation, and platelet degranulation were upregulated. These genetic regulations may explain the immunothrombosis which common cause of morbidity.

Thrombosis is reported to contribute significantly to the severity of COVID-19 symptoms [27–30]. Our results provide evidence at the gene expression level for the role of thrombosis in defining the severity of the disease. Yet, it remains to be determined whether platelet hyperactivation is the cause or result of severe COVID-19 symptoms. Further evidence can be collected by targeted expression analysis of genes in platelet activation/degranulation pathways over the course of the disease and treatment. Notably, the expression of the ACE-2 gene encoding the putative cell entry receptor of SARS-CoV-2 was found to be upregulated in whole blood of CI patients with respect to MI (Table 3) but ACE2 expression level did not differ from NCI. Indeed, it is proposed that SARS-CoV-2 may directly infect and activate megakaryocytes and platelets [30, 31]. Yet, the mechanism of interaction and direct activation remains controversial with contrasting reports on the presence of ACE2 protein expression on platelets. ACE2-mediated or ACE2-independent entry of SARS-CoV-2 to platelets through CD147 and CD26 as the binding partners is both proposed for direct SARS-CoV-2 activation of platelets, leading to thrombosis [28]. According to our results, ACE2 expression in whole blood was elevated in CI patients with respect to MI but CD147 and CD26 were not among the differentially expressed genes in CI patients.

Limitations of this study are limited number of patients and that the study design was cross sectional. Gene expression regulation is actually highly dynamic and gene expression profiles of both CI and MI patients may change during the period of COVID-19 infection in both groups. Following changes in gene expression, patterns with periodic recurrent tests can be useful to reveal infection phase-dependent differences in gene expression between CI and MI patients. Age differential may affect the observed gene expression differences, on the other hand, the fact that majority of downregulated genes in CI patients belong to pathways associated with immune responses imply the effect of glucocorticoid therapy on gene expression. Yet, regardless of age and differences in therapeutic applications, the pool of differentially expressed genes detected in this study unquestionably includes genes that are associated with severe disease symptoms. It is important to note that Favipravir was administered to both CI and NCI patients, which also would cause changes in gene expression regulation. Yet, the gene expression profile of CI patients deviates more significantly from the MI patients compared to NCI individuals. Thus, gene expression differences observed in the present work result from not only differential drug treatments but also differential disease severity in CI and MI individuals.

Overall, it is noteworthy that the transcriptional profile of CI patients deviates more significantly from that of MI in terms of the number of differentially expressed genes. These results imply that genotypic differences may account for the severity of SARS-CoV-2 infection responses. In addition, upregulated blood ACE2 expression in CI patients was observed only compared to MI, supporting the putative role of genotypic differences in disease severity. To resolve genotype – disease susceptibility associations, combined studies that involve both genomic and transcriptomic analyses are essential.

Conclusion

Differential transcriptomic analysis highlights the necessity of genomic association studies, therefore, further work involving the genotyping of large groups of asymptomatic and symptomatic individuals as well as transcriptomic analyses would help determine genotypic associations with the severity of COVID-19 symptoms.

Acknowledgements: We would like to thank TUBITAK, Marmara Research Center, Gene Engineering and Biotechnology Institute for their support of this study.

Ethics Committee Approval: The Medeniyet University Clinical Research Ethics Committee granted approval for this study (date: 23.03.2020, number: 2020/183).

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

Authorship Contributions: Concept – SP; Design – ATU, AOU; Supervision – ST, BCK; Fundings – ST, BCK; Materials – ST, BCK; Data collection and/or processing – BC, HHP; Analysis and/or interpretation – ATU, AOU; Literature review – BC, EO; Writing – BC, ATU, EO; Critical review – SP.

REFERENCES

- Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. J Clin Invest 2021;131:e143380.
- Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med 2020;173:362–7.
- 3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42.
- Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.
- Eastin C, Eastin T. Clinical characteristics of coronavirus disease 2019 in China. J Emerg Med 2020;58:711–2.
- Guthmiller JJ, Stovicek O, Wang J, Changrob S, Li L, Halfmann P, et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. bioRxiv [Preprint] Sep 13, 2020, doi: 10.1101/2020.09.12.294066.
- Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID-19. Blood 2020;136:1317–29.
- Mick E, Kamm J, Pisco AO, Ratnasiri K, Babik JM, Calfee CS, et al. Upper airway gene expression differentiates COVID-19 from other acute respiratory illnesses and reveals suppression of innate immune responses by SARS-CoV-2. medRxiv [Preprint] May 19, 2020, doi: 10.1101/2020.05.18.20105171.
- Bakhshandeh B, Sorboni SG, Javanmard AR, Mottaghi SS, Mehrabi MR, Sorouri F, et al. Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infect Genet Evol 2021;90:104773.

- He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia 2020;34:1637–45.
- Jalili V, Afgan E, Gu Q, Clements D, Blankenberg D, Goecks J, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2020 update. Nucleic Acids Res 2020;48:W395–402.
- 12. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014;30:2114–20.
- 13. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15–21.
- Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014;30:923–30.
- 15. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:550.
- Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44–57.
- Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020;75:1564– 81.
- Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 2020;94:44–8.
- 19. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest 2020;130:2202–5.
- Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al; Massachusetts Consortium for Pathogen Readiness. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun 2020;11:5493.
- Rodrigues TS, de Sá KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med 2021;218:e20201707.

- Hu W, Yen YT, Singh S, Kao CL, Wu-Hsieh BA. SARS-CoV regulates immune function-related gene expression in human monocytic cells. Viral Immunol 2012;25:277–88.
- 23. Thiel V, Weber F. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev 2008;19:121–32.
- 24. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol 2020;11:1949.
- Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020;18:1995–2002.
- Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.
- 27. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:2950–73.
- Campbell RA, Boilard E, Rondina MT. Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets? J Thromb Haemost 2021;19:46–50.
- 29. McFadyen JD, Stevens H, Peter K. The emerging threat of (Micro) thrombosis in COVID-19 and its therapeutic implications. Circ Res 2020;127:571–87.
- Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol 2020;13:120.
- Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19. Circ Res 2020;127:1404–18.